Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast, Advisory

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference


DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and Chief Executive Officer, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 10:00 am ET. Mr. Pauls looks forward to meeting investors to discuss DiaMedica's clinical development programs and business strategy.

If you are interested in arranging a one-on-one meeting or listening to the live event, please contact your BTIG conference representative.

About DiaMedica Therapeutics

DiaMedica Therapeutics is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Our lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, we are advancing DM199 in our REMEDY Phase 2/3 trial in the treatment of AIS and completing enrollment in our REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.


These press releases may also interest you

at 05:05
The "Global Genome Editing Market, By Technique (CRISPR, TALENs, Zinc Finger Nucleases, Others), By Application (Cell Line Engineering, Animal Genetic Engineering, Others), By Delivery Method, By End User, By Region, Competition Forecast &...

at 05:05
Tubulis today announced the formation of a Scientific Advisory Board (SAB) with the appointment of international industry experts in the development of antibody drug conjugates (ADCs) and in-depth knowledge in the therapeutic areas of oncology and...

at 05:00
The "Advanced Renal Cell Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Advanced Renal Cell Carcinoma...

at 05:00
The Home Fitness Equipment Market in the Personal Products industry is poised to grow by USD 1.90 billion during 2021-2025, at a CAGR of 7.48%. This report offers an up-to-date analysis regarding the current market scenario, the latest trends and...

at 05:00
Zing Health, a Chicago-based provider of Medicare Advantage health plans, is teaming with St. Louis-based Balto to enhance its customer service and inbound sales using advanced call center technology guided by artificial intelligence (AI)....

at 05:00
Vyrtytm Corporation (the "Company), doing business as, Sync.MD®, a privately-held innovative medical data company, today confirmed that it had successfully raised US $ 10 million in a Series B round of equity financing. This most recent round of...



News published on 28 july 2021 at 16:30 and distributed by: